ripekg:evaluation/RIPEA5A5547915735AD6D |
prov:used |
ripekg:registry-evidence/RIPEA5A5547915735AD6D |
ripekg:registry-evidence/RIPEA5A5547915735AD6D |
rdf:type |
rdfs:Resource |
ripekg:registry-evidence/RIPEA5A5547915735AD6D |
rdf:type |
owl:Thing |
ripekg:registry-evidence/RIPEA5A5547915735AD6D |
rdf:type |
ripe:IntegrityAssessmentEvidenceIntegrity assessment evidence |
ripekg:registry-evidence/RIPEA5A5547915735AD6D |
rdf:type |
ripe:RegistryEvidenceRegistry evidence |
ripekg:registry-evidence/RIPEA5A5547915735AD6D |
rdf:type |
tido:Evidence |
ripekg:registry-evidence/RIPEA5A5547915735AD6D |
prov:wasAttributedTo |
ripekg:source/clinicaltrials-govClinicalTrials.gov |
ripekg:registry-evidence/RIPEA5A5547915735AD6D |
prov:wasGeneratedBy |
ripekg:evidence-aggregation/RIPEA5A5547915735AD6D |
ripekg:registry-evidence/RIPEA5A5547915735AD6D |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA5A5547915735AD6D |
ripekg:registry-evidence/RIPEA5A5547915735AD6D |
ripe:concerns |
ripekg:work/10.3390%2Fnu17071246Effects of Vitamin D3 Treatment on Polycystic Ovary Symptoms: A Prospective Double-Blind Two-Phase Randomized Controlled Clinical Trial |
ripekg:registry-evidence/RIPEA5A5547915735AD6D |
ripe:isProspective |
false |
ripekg:registry-evidence/RIPEA5A5547915735AD6D |
ripe:registrationAssessmentRationale |
Comparison performed at month level. Registration: 2021-04, LLM Recruitment Start: 2016-12. Deemed retrospective at month level. |
ripekg:registry-evidence/RIPEA5A5547915735AD6D |
ripe:registrationDate |
08-04-2021 |
ripekg:registry-evidence/RIPEA5A5547915735AD6D |
ripe:registrationId |
NCT04840238 |
ripekg:registry-evidence/RIPEA5A5547915735AD6D |
ripe:registrationLink |
https://clinicaltrials.gov/study/NCT04840238 |
ripekg:registry-evidence/RIPEA5A5547915735AD6D |
ripe:registryName |
ClinicalTrials.gov |
ripekg:registry-evidence/RIPEA5A5547915735AD6D |
tido:supports |
ripekg:integrity-assessment-hypothesis/RIPEA5A5547915735AD6D-inspectai-2-2 |